Caitong International Asset Management’s Heart Test Laboratories HSCS Stock Holding History

Caitong International Asset Management’s Portfolio HSCS Stock Details HSCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20	Buy	+8	New	+$16	﹤0.01%	2519

Other funds holding HSCS

TFB Advisors Overland Park, Kansas $227M AUM 26.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ASW

Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TWM

Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Caitong International Asset Management's HSCS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Heart Test Laboratories (HSCS) in Q2 2026: 8 shares worth $20. The stake represents ﹤0.01% of the portfolio and ranks #2519 among its holdings.

16 funds tracked by Wall St. Rank hold HSCS as of Q2 2026.

Caitong International Asset Management held 8 shares of Heart Test Laboratories worth $20 as of Q2 2026.
Heart Test Laboratories was a new Caitong International Asset Management position in Q2 2026.
Heart Test Laboratories made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2519 holding.
16 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.